CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Syncona Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Syncona Ltd
3Rd Floor
Arnold House, St Julian's Avenue
SAINT PETER PORT, GY1 3RD  Guernsey Ticker: SYNCSYNC
Business Summary
Syncona Limited is a Guernsey-based closed-ended investment company. The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
6799 Investors, not elsewhere classified
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MelanieGee 1/1/2020 6/4/2019
Interim Chairman and Chief Executive Officer of Syncona Investment Management Limited Christopher J.Hollowood 11/16/2023 1/1/2017
Managing Partner, Head of Investments of Syncona Investment Management Limited RoelBulthuis 1/1/2022 1/1/2022
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Freeline Therapeutics Holdings PLC (ADR) Sycamore House STEVENAGE United Kingdom
Applied Genetic Technologies Corp 14193 NW 119th Terrace Alachua Florida United States
SwanBio Therapeutics, Inc. 3624 Market Street Philadelphia PA United States

Business Names
Business Name
Applied Genetic Technologies Corp
BACT
Freeline Therapeutics Holdings PLC (ADR)
SwanBio Therapeutics, Inc.
SYNC

General Information
Outstanding Shares: 632,214,994 (As of 11/18/2024)
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024